| Number: 201303012 |
Principal Investigator: Schroeder, Mark |
| Title: Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation |
| Description: This research study aims to discover the side effects and highest dose of a drug called
azacitidine that can be given after a stem cell transplant to help prevent or minimize the effects of graft-versus-host disease (GVHD). We will also look at the way azacitidine might affect whether or how a pers...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201211047 |
Principal Investigator: DiPersio, John |
| Title: A Pilot Study of Brentuximab Vedotin for the Prevention of Graft-Versus-Host Disease (GVHD) after Mismatched Unrelated Allogeneic Stem Cell Transplantation |
| Description: The purpose of this research study is discover the side effects and highest dose of a drug called brentuximab vedotin that can be given when receiving other drugs to help prevent or minimize the effects of graft-versus-host disease (GVHD)....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201208046 |
Principal Investigator: Vij, Ravi |
| Title: A Phase II Study of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) as Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation for Multiple Myeloma |
| Description: The purpose of this research study is to see if the combination of bortezomib added to the drug regimen BEAM will be an effective treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201112026 |
Principal Investigator: DiPersio, John |
| Title: A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies |
| Description: The purpose of this research study is to see whether donors who are treated with the new drug POL6326 are able to produce enough stem cells for transplant after one dose of the study drug (as compared to other drugs used for the same purpose, which may require multiple collections). We are also loo...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201108083 |
Principal Investigator: Schroeder, Mark |
| Title: A Phase II Trial Evaluating the Safety and Efficacy of Plerixafor and Sargramostim (GM-CSF) for the Mobilization of Peripheral Blood Stem Cells (PBSCs) from Normal HLA-Matched Allogeneic Sibling Donors |
| Description: The main purpose of this study is to gather information about the combination of the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). This study will look at how safe this combination is and how patients tolerate the treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201101864 |
Principal Investigator: Stockerl-Goldstein, Keith |
| Title: Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma |
| Description: You may be invited to participate in a research study to treat non-Hodgkin’s lymphoma. The treatment plan consists of an autologous hematopoietic (blood) cell transplant followed by a non-myeloablative allogeneic transplantation (transplant from another individual). An autologous transplant is don...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201011859 |
Principal Investigator: DiPersio, John |
| Title: A pilot study of GCSF +/- Plerixafor (AMD3100) mobilized donor CD34+ enriched peripheral blood mononuclear cells for the treatment of allogeneic stem cell transplant recipients with limited donor engraftment |
| Description: This study will evaluate if giving a “boost” of T-cell depleted, enriched stem cells (known as CD34+ cells) can improve patients' blood counts following an allogeneic stem cell transplant....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201111096 |
Principal Investigator: Westervelt, Peter |
| Title: Multi-center single arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for non-remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) regimen |
| Description: The purpose of this research study is to study a new method of full intensity, pre-treatment (or conditioning) called CloBu4, using the drugs Clofarabine and Busulfan....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201109177 |
Principal Investigator: Pusic, Iskra |
| Title: A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation |
| Description: The purpose of this research study is to see if cutaneous sclerosis improves with the use of Rituximab or Imatinib....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104235 |
Principal Investigator: Pusic, Iskra |
| Title: Targeted Therapy of Bronchiolitis Obliterans Syndrome |
| Description: The purpose of this research study is to see if an investigational combination of three drugs is safe and effective in treating BOS after allogeneic hematopoietic cell transplant....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102463 |
Principal Investigator: Fehniger, Todd |
| Title: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor |
| Description: This study is investigating a newer donor selection factor, KIR genotyping, in addition to HLA testing and other donor selection factors....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 100801 |
Principal Investigator: Vij, Ravi |
| Title: Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML |
| Description: The purpose of this study is to find out what effects (good and bad) this treatment has on patients and their cancer. This study is adding the drug azacitidine to a transplant, to see if it improves the outcome of the transplant.
This research is being done to improve the outcome of patients diag...MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 100701 |
Principal Investigator: Vij, Ravi |
| Title: Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) |
| Description: The purpose of this study is to find out what effects (good and bad) this treatment has on patients and this type of cancer.
This research is being done to improve the outcomes of patients diagnosed with chronic lymphocytic leukemia who may have high risk features or who have had their disease r...MORE |
| ___________________________________________________________________________________________________ |
| Number: BMT CTN 0803 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV infected patients.(CTN 0803) |
| Description: This study is for patients who have an HIV related chemotherapy-sensitive aggressive B cell lymphoma or Hodgkin’s lymphoma which has either not fully responded to the initial treatment or has returned.
Patients on this study will undergo and autologous peripheral blood stem cell transplant. An...MORE |
| ___________________________________________________________________________________________________ |
| Number: BMT CTN 0801 |
Principal Investigator: Westervelt, Peter |
| Title: A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, Sirolimus/Extracorporeal Photopheresis plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease.(CTN 0801) |
| Description: The primary goals of this study are to compare three treatments for chronic graft-versus-host disease (GVHD), and evaluate how well chronic GVHD responds to the treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201207064 |
Principal Investigator: Westervelt, Peter |
| Title: A Phase II Controlled Trial of a Single Prohema-CB unit(Ex Vivo Modulated Human Cord Blood Cells)As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies |
| Description: The purpose of this research study is to determine the effects of the ProHema-CB treatment on umbilical cord blood units to be used in transplantation. ProHema-CB treatment is being tested to see if it can improve the ability of umbilical cord blood stem cells to grow after transplantation....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104236 |
Principal Investigator: Pusic, Iskra |
| Title: Longitudinal Study of Immune Mediated Disorders after Allogeneic Hematopoietic Cell Transplantation |
| Description: The purpose of this research study is to better understand the onset and course of GVHD and other immune mediated disorders after stem cell transplant by identifying and describing when these disorders happen, and the course they take . We also will collect specimens for future research studies....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209074 |
Principal Investigator: Dubberke, Erik |
| Title: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation |
| Description: The purpose of this research study is to determine if fidaxomicin is safe and effective in the prevention of clostridium difficile-associated diarrhea, or CDAD, compared with placebo. As there is currently no other drug on the market used to prevent CDAD before it occurs, the information obtained fr...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201111199 |
Principal Investigator: Lawrence, Steven |
| Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs) |
| Description: The purpose of the study is to see if the virus that causes shingles is present, and if it is, if it is the virus that causes natural shingles or the vaccine virus.
...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102099 |
Principal Investigator: Allen, Paul |
| Title: T Cell Receptor Analysis in Hematopoietic Stem Cell Transplantation and Graft versus Host Disease |
| ___________________________________________________________________________________________________ |
| Number: 201212113 |
Principal Investigator: Dubberke, Erik |
| Title: Evolution of CMV in Allogeneic Hematopoietic Cell Transplant Recipients |
| ___________________________________________________________________________________________________ |